170 related articles for article (PubMed ID: 23291942)
1. A CpG-containing oligodeoxynucleotide adjuvant for acellular pertussis vaccine improves the protective response against Bordetella pertussis.
Asokanathan C; Corbel M; Xing D
Hum Vaccin Immunother; 2013 Feb; 9(2):325-31. PubMed ID: 23291942
[TBL] [Abstract][Full Text] [Related]
2. Adjuvanticity of native and detoxified adenylate cyclase toxin of Bordetella pertussis towards co-administered antigens.
Macdonald-Fyall J; Xing D; Corbel M; Baillie S; Parton R; Coote J
Vaccine; 2004 Oct; 22(31-32):4270-81. PubMed ID: 15474718
[TBL] [Abstract][Full Text] [Related]
3. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children.
Podda A; Carapella De Luca E; Titone L; Casadei AM; Cascio A; Bartalini M; Volpini G; Peppoloni S; Marsili I; Nencioni L
J Pediatr; 1993 Jul; 123(1):81-4. PubMed ID: 8320630
[TBL] [Abstract][Full Text] [Related]
5. Storage at -3 degrees C for 24 h alters the immunogenicity of pertussis vaccines.
Boros CA; Hanlon M; Gold MS; Roberton DM
Vaccine; 2001 May; 19(25-26):3537-42. PubMed ID: 11348721
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant effects of adenylate cyclase toxin of Bordetella pertussis after intranasal immunisation of mice.
Orr B; Douce G; Baillie S; Parton R; Coote J
Vaccine; 2007 Jan; 25(1):64-71. PubMed ID: 16916566
[TBL] [Abstract][Full Text] [Related]
7. Investigation of cellular and humoral immune responses to whole cell and acellular pertussis vaccines.
Canthaboo C; Williams L; Xing DK; Corbel MJ
Vaccine; 2000 Nov; 19(6):637-43. PubMed ID: 11090715
[TBL] [Abstract][Full Text] [Related]
8. Pertactin deficient Bordetella pertussis present a better fitness in mice immunized with an acellular pertussis vaccine.
Hegerle N; Dore G; Guiso N
Vaccine; 2014 Nov; 32(49):6597-600. PubMed ID: 25312274
[TBL] [Abstract][Full Text] [Related]
9. Synergic effect of genotype changes in pertussis toxin and pertactin on adaptation to an acellular pertussis vaccine in the murine intranasal challenge model.
Komatsu E; Yamaguchi F; Abe A; Weiss AA; Watanabe M
Clin Vaccine Immunol; 2010 May; 17(5):807-12. PubMed ID: 20357056
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.
Knight JB; Huang YY; Halperin SA; Anderson R; Morris A; Macmillan A; Jones T; Burt DS; Van Nest G; Lee SF
Clin Exp Immunol; 2006 Jun; 144(3):543-51. PubMed ID: 16734625
[TBL] [Abstract][Full Text] [Related]
11. Novel vaccine formulations against pertussis offer earlier onset of immunity and provide protection in the presence of maternal antibodies.
Polewicz M; Gracia A; Garlapati S; van Kessel J; Strom S; Halperin SA; Hancock RE; Potter AA; Babiuk LA; Gerdts V
Vaccine; 2013 Jun; 31(31):3148-55. PubMed ID: 23684829
[TBL] [Abstract][Full Text] [Related]
12. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis.
Storsaeter J; Hallander HO; Gustafsson L; Olin P
Vaccine; 1998 Dec; 16(20):1907-16. PubMed ID: 9796042
[TBL] [Abstract][Full Text] [Related]
13. Long-term immunogenicity of a single dose of acellular pertussis vaccine in paediatric health-care workers.
Littmann M; Hülsse C; Riffelmann M; Wirsing von König CH
Vaccine; 2008 May; 26(19):2344-9. PubMed ID: 18396360
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of chemically cross-linked antigens for acellular pertussis vaccine.
Watanabe M; Nagai M; Funaishi K; Endoh M
Vaccine; 2000 Dec; 19(9-10):1199-203. PubMed ID: 11137257
[TBL] [Abstract][Full Text] [Related]
15. Immune responses to pertussis antigens eight years after booster immunization with acellular vaccines in adults.
Tran Minh NN; He Q; Edelman K; Putto-Laurila A; Arvilommi H; Viljanen MK; Mertsola J
Vaccine; 2000 Apr; 18(19):1971-4. PubMed ID: 10706957
[TBL] [Abstract][Full Text] [Related]
16. Intranasal Immunization with Acellular Pertussis Vaccines Results in Long-Term Immunity to Bordetella pertussis in Mice.
Wolf MA; Boehm DT; DeJong MA; Wong TY; Sen-Kilic E; Hall JM; Blackwood CB; Weaver KL; Kelly CO; Kisamore CA; Bitzer GJ; Bevere JR; Barbier M; Damron FH
Infect Immun; 2021 Feb; 89(3):. PubMed ID: 33318136
[No Abstract] [Full Text] [Related]
17. Investigation of role of nitric oxide in protection from Bordetella pertussis respiratory challenge.
Canthaboo C; Xing D; Wei XQ; Corbel MJ
Infect Immun; 2002 Feb; 70(2):679-84. PubMed ID: 11796599
[TBL] [Abstract][Full Text] [Related]
18. Pertactin-Negative and Filamentous Hemagglutinin-Negative Bordetella pertussis, Australia, 2013-2017.
Xu Z; Octavia S; Luu LDW; Payne M; Timms V; Tay CY; Keil AD; Sintchenko V; Guiso N; Lan R
Emerg Infect Dis; 2019 Jun; 25(6):1196-1199. PubMed ID: 31107218
[TBL] [Abstract][Full Text] [Related]
19. Increasing FIM2/3 antigen-content improves efficacy of Bordetella pertussis vaccines in mice in vivo without altering vaccine-induced human reactogenicity biomarkers in vitro.
Queenan AM; Dowling DJ; Cheng WK; Faé K; Fernandez J; Flynn PJ; Joshi S; Brightman SE; Ramirez J; Serroyen J; Wiertsema S; Fortanier A; van den Dobbelsteen G; Levy O; Poolman J
Vaccine; 2019 Jan; 37(1):80-89. PubMed ID: 30478007
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of a three-component acellular pertussis vaccine administered at birth.
Belloni C; De Silvestri A; Tinelli C; Avanzini MA; Marconi M; Strano F; Rondini G; Chirico G
Pediatrics; 2003 May; 111(5 Pt 1):1042-5. PubMed ID: 12728086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
